

# VALNEVA SE

ISIN: FR0004056851

WKN: -

Asset Class: **Stock**

## Company

2024/07/16 17:35:09

Price

**3.49** EURDifference ▲ 4.05%(0.14)

## Contact Details

VALNEVA SE

Tel: +33-2-28-07-37-10

- -

Fax: +

Campus Bio-Ouest, 6, rue Alain  
Bombard

Web:

<http://www.valneva.com>

44800 Saint-Herblain

E-mail:

[info@valneva.com](mailto:info@valneva.com)

## Company Profile

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	262,824,000		424,660,000		585,832,000	
<b>Common stock capital</b>		20,837,000		20,755,000		15,786,000
<b>Fixed assets</b>	206,567,000		207,940,000		240,202,000	
<b>Equity capital of a company</b>		128,247,000		219,797,000		170,582,000
<b>Cash and cash equivalents</b>	126,080,000		289,431,000		346,686,000	
<b>Accrued liabilities</b>		1,074,000		1,320,000		8,308,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		158,863,000		277,392,000		368,979,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		182,281,000		135,411,000		286,473,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		6,382,000		6,751,000		163,780,000
<b>Total assets</b>	469,391,000	469,391,000	632,600,000	632,600,000	826,034,000	826,034,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	676	-	-
<b>Equity ratio</b>	27.32%	34.75%	20.65%
<b>Debt-equity ratio</b>	266.01%	187.81%	384.24%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	3.79%	10.54%	20.13%

## Income statement

	2023	2022	2021
<b>Turnover</b>	153,713,000	361,303,000	348,086,000
<b>Net income</b>	-101,429,000	-143,279,000	-73,425,000
<b>EBIT</b>	-83,311,000	-141,378,000	-75,209,000
<b>Operating income before taxes</b>	-105,426,000	-160,172,000	-91,923,000
<b>Cash Flow</b>	-214,102,000	-254,294,000	68,538,000
<b>Net interest income</b>	-22,115,000	-18,794,000	-16,714,000
<b>Research and development expenses</b>	56,894,000	101,322,000	168,583,000
<b>Income taxes</b>	-3,997,000	-16,884,000	-18,503,000
<b>Result from investments in subsidiaries, associates and other</b>	0	9,000	-5,000
<b>Revenues per employee</b>	227,386	-	-

## Board of Directors

Anne-Marie Graffin	Chairman of Supervisory Board
Kathrin Jansen	Member of Supervisory Board
Danièle Guyot-Caparros	Member of Supervisory Board
James Connolly	Member of Supervisory Board
James Sulat	Member of Supervisory Board
Maïlys Ferrère	Member of Supervisory Board

## Members of Management Board

Thomas Lingelbach	Chairman of Managing Board
Dipal Patel	Member of Executive Committee
Franck Grimaud	Member of Executive Committee
Frederic Jacotot	Member of Executive Committee
Juan Carlos Jaramillo	Member of Executive Committee
Peter Bühler	Member of Executive Committee
Petra Pesendorfer	Member of Executive Committee
Vincent Dequenne	Member of Executive Committee